CompletedNot Applicable

Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients

Switzerland80 participantsStarted 2021-05-07

Plain-language summary

CLAD is defined as loss of lung function after other factors, particularly infections have been excluded. Readily accessible diagnostic procedures to detect acute cellular rejection at the earliest possible occasion is crucial for posttransplant survival. Serial lung function tests, laboratory testing and pulmonary imaging are only clinical indicators of chronic allograft dysfunction in lung transplant recipients. Since forceps biopsy to detect acute cellular rejection in lung transplant recipients has several shortcomings, the purpose of this study is to investigate a new biopsy technique using the transbronchial cryoprobe.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * routinely performed surveillance bronchoscopy and when indicated including serial FB and CB in the same session in patients wo had undergone lung transplant * male or female subject of at least 18 years of age * written informed consent after participant's information signed by patient Exclusion Criteria: * age \< 18 years * Lacking ability to form an informed consent (including impaired judgement, communication barriers) * Contraindication against bronchoscopy (e.g. co-morbidities) * INR \> 2 or Thrombocytes \< 50000 * Double antiplatelet drugs (e.g. ASS and Clopidogrel) within 7 days before biopsy * Anticoagulation with NOAK within 48 hours before biopsy * Moderate or severe pulmonary hypertension (mPAP \> 30 mmHg, RV/RA \>30 mmHg)

What they're measuring

diagnostic yield

Timeframe: up to 1 month

Trial details

NCT IDNCT05006742

SponsorUniversity of Zurich

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-31